Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 3831 versus olanzapine for body weight effects in young adults early in schizophrenia, schizophreniform disorder, or bipolar I disorder
MOH_2017-08-10_000716Phase 3Recruiting
- Sponsor
- Alkermes
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of olanzapine + samidorphan, olanzapine and samidorphan in schizophrenia, schizophreniform disorder and bipolar I disorder (2 arms), sponsored by Alkermes. Started Aug 2017; status: recruiting.
02
Drugs
olanzapine + samidorphanolanzapinesamidorphan
03
Conditions
schizophreniaschizophreniform disorderbipolar I disorder
Beyond the preview
Go deeper on MOH_2017-08-10_000716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-10_000716.